Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 10,624 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Osteoporosis
Interventions: raloxifene HCI and alendronate Na; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years to 80 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 73
States / cities: Anniston, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 70 more

Conditions: Gastrointestinal Dysmotility
Interventions: Saline Solution for Injection, Ipamorelin; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 45
States / cities: Florence, Alabama • Sheffield, Alabama • Fountain Valley, California + 42 more

Conditions: Suicide, Mental Health Disorder, Anhedonia
Interventions: ViraSafe: Treatment pushes, BRITE; Behavioral
Lead sponsor: Ksana Health; Industry
Eligibility: 13 Years to 24 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Eugene, Oregon • Pittsburgh, Pennsylvania

Conditions: Down Syndrome
Interventions: Promoting Health through Parent Empowerment and the Activation of Routines, Enhanced Usual Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Months and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Interventions: Surufatinib in combination with Gemcitabine; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 11
States / cities: Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 8 more

Conditions: Urinary Tract Infection
Interventions: Cefixime, Cephalexin, Placebo, Trimethoprim/Sulfamethoxazole; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Months to 10 Years
Enrollment: 717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Osteoporosis
Interventions: Zoledronic Acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 65 Years to 89 Years · Female only
Enrollment: 7,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 59
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 50 more

Conditions: Lung Cancer
Interventions: cisplatin, docetaxel, gemcitabine hydrochloride, pemetrexed disodium, vinorelbine tartrate, standard follow-up care; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 93
States / cities: Anniston, Alabama • Birmingham, Alabama • Burbank, California + 66 more

Conditions: HIV Infections
Interventions: SP01A; Drug
Lead sponsor: Samaritan Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 7
States / cities: Fort Lauderdale, Florida • Miami, Florida • Orlando, Florida + 4 more

Conditions: Schizophrenia, Bipolar Disorder
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 9,356 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • No. Little Rock, Arkansas + 22 more

Conditions: Bladder Cancer
Interventions: Vicinium; Biological
Lead sponsor: Sesen Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Leukemia
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone, tacrolimus, laboratory biomarker analysis, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation; Biological · Drug · Other + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 45 more

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 28
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Encinitas, California + 24 more

Conditions: B-cell Chronic Lymphocytic Leukemia
Interventions: Lenalidomide, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 56
States / cities: Phoenix, Arizona • Fountain Valley, California • San Diego, California + 48 more

Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Interventions: 27T51, Cemiplimab, Bevacizumab; Other · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Boston, Massachusetts • Hackensack, New Jersey • Buffalo, New York + 2 more

Conditions: Cancer
Interventions: Dabrafenib, Trametinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 15
States / cities: Los Angeles, California • Orange, California • Aurora, Colorado + 11 more

Conditions: Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions: XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor); Device · Drug
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 54
States / cities: Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more

Conditions: Metastatic Solid Tumor, Advanced Solid Tumor
Interventions: CHS-114, Toripalimab, 5 Fluorouracil, Cisplatin; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 20
States / cities: Tucson, Arizona • Duarte, California • Aurora, Colorado + 16 more

Conditions: Migraine
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 27
States / cities: Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 18 more

Conditions: Hemophilia A
Interventions: SB-525 (PF-07055480); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 22
States / cities: Little Rock, Arkansas • Duarte, California • Sacramento, California + 7 more

Conditions: Chronic Bronchitis
Interventions: RheOx Bronchial Rheoplasty, Sham Procedure; Device
Lead sponsor: Gala Therapeutics, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more

Conditions: Endometrial Neoplasms
Interventions: olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years · Female only
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 50
States / cities: Tucson, Arizona • Concord, California • La Jolla, California + 45 more

Conditions: Lumbar Spinal Stenosis
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 90 Years
Enrollment: 239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2023
U.S. locations: 7
States / cities: Denver, Colorado • Decatur, Georgia • Ann Arbor, Michigan + 4 more

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Sunitinib, GM-CSF, Cyclophosphamide, IMA901; Drug · Biological
Lead sponsor: Immatics Biotechnologies GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 17
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 14 more

Search by objective public record fields.

EVA: Evista Alendronate Comparison

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents

Promoting Health Through Parent Empowerment and the Activation of Routines (PrO-PEAR)

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

HORIZON-PFT: Pivotal Fracture Trial

Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer

A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients

CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness

Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

XIENCE 28 USA Study

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Predictors of Decompressive Laminectomy Outcomes

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma